Abdul Khan, MD
Psychiatry · Baton Rouge, LANPI 1356658116
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $124,305 of the $155,708 with a category attached, or 79.8%. Alkermes, Inc. accounts for 60.2% of it on its own, with 23 other manufacturers making up the rest. 2025 is the largest year on record at $97,686, more than ten times the $290 reported in 2019. Among psychiatry clinicians in LA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 545 payments — averaging $285.70 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Alkermes, Inc.$94K
- Axsome Therapeutics, Inc.$56K
- AbbVie$1K
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$623
- Johnson & Johnson$590
- Takeda Pharmaceuticals U.S.A., Inc.$469
- plus $3K from 18 others
What the payments were for
- Consulting fees$9,4306%
- Speaking & faculty fees$124,30580%
- Travel & lodging$10,2617%
- Food & beverage$11,6948%
- Education$180%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Alkermes, Inc. | 112 | $93,698 |
| Axsome Therapeutics, Inc. | 90 | $56,232 |
| AbbVie(2 entities) | 99 | $1,343 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 43 | $623 |
| Johnson & Johnson | 33 | $590 |
| Takeda Pharmaceuticals U.S.A., Inc. | 31 | $469 |
| Neurocrine Biosciences, Inc. | 21 | $402 |
| Vanda Pharmaceuticals Inc. | 17 | $351 |
| Indivior Inc. | 15 | $316 |
| E.r. Squibb & Sons, L.L.C. | 14 | $302 |
| Bausch Health US, LLC | 13 | $270 |
| Otsuka America Pharmaceutical, Inc. | 14 | $254 |
| Supernus Pharmaceuticals, Inc. | 9 | $230 |
| Lundbeck LLC | 12 | $228 |
| Teva Pharmaceuticals USA, Inc. | 6 | $108 |
| Ironshore Pharmaceuticals Inc. | 4 | $72 |
| Almatica Pharma LLC | 3 | $58 |
| Neuronetics, Inc. | 2 | $38 |
| Luye Pharma (USA) Ltd. | 2 | $36 |
| Idorsia Pharmaceuticals US Inc | 1 | $22 |
| Eisai Inc. | 1 | $17 |
| Xeris Pharmaceuticals, Inc. | 1 | $17 |
| Avanir Pharmaceuticals, Inc. | 1 | $17 |
| Jazz Pharmaceuticals Inc. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$155,708 in reported general payments places this provider in the 95th percentile of 474 psychiatry providers in Louisiana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Invega SustennaPaliperidone Palmitate | 17 | $60,849 |
| VraylarCariprazine Hcl | 11 | $15,654 |
| JanuviaSitagliptin Phosphate | 12 | $6,443 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 22 | $2,006 |
| Bupropion XlBupropion Hcl | 44 | $1,810 |
| Quetiapine Fumarate | 70 | $887 |
| Trazodone Hcl | 36 | $847 |
| Amitriptyline Hcl | 34 | $508 |
| Venlafaxine Hcl ErVenlafaxine Hcl | 42 | $492 |
| Propranolol Hcl | 38 | $450 |
| Oxcarbazepine | 16 | $412 |
| Olanzapine | 22 | $322 |
| Fluoxetine Hcl | 36 | $320 |
| Gabapentin | 14 | $274 |
| Aripiprazole | 24 | $252 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Johnson & JohnsonInvega Sustenna | $590 | $60,84917 claims |
| AbbVieVraylar | $1,343 | $15,65411 claims |
| Almatica Pharma LLCSertraline Hcl | $58 | $7819 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 474 psychiatry providers in Louisiana.
Other psychiatry in Baton Rouge
- Larry WarnerBaton Rouge$495K
- Donna FargasonBaton Rouge$11K
- Aniedi UdofaBaton Rouge$9K
- Sudheera RachamalluBaton Rouge$7K
- Jason BoudreauxBaton Rouge$5K
- Anupama AtluriBaton Rouge$5K
- Patrick HayesLake Charles$837K
- Maria CruseThibodaux$522K
- Gregory BrownShreveport$495K
- Arwen PodestaNew Orleans$466K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.